今年:卵巢癌维持治疗势在必行-科医诊断|北京yabo亚博网站,亚博全站app下载|官网
【专家共识】非小细胞肺癌免疫检查点抑制剂治疗与疗效评价

下一篇

今年:卵巢癌维持治疗势在必行




JUST FOR YOUR HEALTH



[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66:115-132.
[2] 周琦,吴小华,刘继红,等.中国卵巢上皮性癌维持治疗专家共识(2019)[J].中国实用妇科与产科杂志,2019,35(6):655-659.
[3] Konstantinopoulos PA,Ceccaldi R,Shapiro GI,et al.Homologous recombination deficiency:exploiting the fundamental vulnerability of ovarian cancer[J].Cancer discovery, 2015, 5(11): 1137-1154.

[4] Moore K,Colombo N,Scambia G,et al.Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer [J].N Engl J Med,2018,379(26):2495-2505.
[5] González-Martín A,Pothuri B,Vergote I,et al.Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer[J]. NEngl J Med,2019,381(25):2391-2402.
[6] Ray-Coquard IL,Pautier P,et al. Phase Ⅲ PAOLA-1/EN-GOT-ov25 trial:Olaparib plus bevacizumab(bev)as maintenance therapy in patients (pts) with newly diagnosed,advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev[R].LBA2_PR presented at ESMO Annual Conference 2019,27 September-1 October,Barcelona,Spain.

[7] Korkmaz T,Seber S,Basaran G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials[J].Crit Rev Oncol Hematol,2016,98:180-188.
[8] Pujade-Lauraine E,Ledermann JA,Selle F,et al.Olaparib tablets as maintenance therapy in patients with platinum sensitive ,relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2 /ENGOT-Ov21):adouble-blind,randomised,placebo controlled, phase 3 trial [J]. Lancet Oncol, 2017,18 (9): 1274-1284.
[9] Ledermann J,Harter P,Gourley C.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer:a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J].Lancet Oncol, 2014,15(4):852-861.
[10] Ledermann J,Harter P,Gourley C,et al.Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer[J]. NEngl J Med,2012,366:1382-1392.
[11] Coleman RL,Oza AM,Lorusso D,et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy(ARIEL3):a randomised, double-blind, placebo-controlled, phase 3 trial[J]. The Lancet, 2017, 390(10106): 1949-1961.
[12] Mirza MR,Monk BJ,Herrstedt J,et al.Niraparib Maintenance Therapy in Platinum-Sensitive,Recurrent Ovarian Cancer[J].N Engl J Med,2016,375(22):2154-2164. 


上一篇

三代EGFR抑制剂阿美替尼与奥希替尼对比:如何选择?

2020/6/12 14:02:00

yabo亚博网站_亚博足球_亚博全站app下载 本网站由阿里云提供云计算及安全服务 Powered by CloudDream
Baidu
sogou